Impact Events
More| Date | Lead Company | Event | Type | Approval Change | Approval Likelihood |
|---|---|---|---|---|---|
| 6/17/26 | Alkermes (ALKS) | alixorexton for Narcolepsy | Subscribers Only | Subscribers Only | Subscribers Only |
| 6/15/26 | Aptose (APTO) | tuspetinib for Acute Myelogenous Leukemia (AML) | Subscribers Only | Subscribers Only | Subscribers Only |
| 6/15/26 | Halia | HT-6184 for Myelodysplastic Syndrome (MDS) | Subscribers Only | Subscribers Only | Subscribers Only |
| 6/14/26 | Crinetics (CRNX) | atumelnant for Congenital Adrenal Hyperplasia (CAH) | Subscribers Only | Subscribers Only | Subscribers Only |
| 6/14/26 | Johnson & Johnson (JNJ) | Tecvayli for Multiple Myeloma (MM) | Subscribers Only | Subscribers Only | Subscribers Only |
Upcoming Catalysts
More| Expected Date Range | Lead Company | Drug | Expected Catalyst |
|---|---|---|---|
| 06/25/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
| 06/25/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
| 06/26/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
| 09/08/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
| 09/17/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |